SPERA™ COVID-19 Ag Test - Carton Order (200 Tests)
$1,980.00Price
Excluding Sales Tax
200 individual tests per carton. Each carton includes 20 kit boxes of 10 tests. Limit of 5 Cartons (1,000 tests) per order.
top of page
Product Description
The SPERA™ COVID-19 Antigen Test is an easy to use, high quality rapid SARS-CoV-2 antigen test with an industry leading sensitivity rate of 92% and specificity rate of 97%. FDA authorized at the point-of-care, the SPERA™ COVID-19 Ag tests is specifically designed for high volume and efficient testing to support a safer return to schools, travel and workplaces.
Made in Japan. Best-in-class Japanese manufacturing, the SPERA™ COVID-19 Antigen Test is a premium and highly effective test, verified to be effective against major circulating variants including the Delta variant as well as the Alpha, Beta and Gamma.
Fast, Reliable, Effective and Affordable. The SPERA™ COVID-19 Antigen Test is an optimal testing solution for healthcare professionals who value high quality testing in outpatient clinical centers. Multiple SPERA™ COVID-19 Antigen tests can be run in parallel in small spaces without operating any complex and slow instruments while maintaining test accuracy and reliability.
Effective Against Variants
Proven to detect all known variants including Omicron, Delta and Lambda.
Specifications
GTIN
00860007598708
Tests Per Kit
10
Test Kits Per Carton
20
Total Tests Per Carton
200
Test Kit Dimensions (LxWxH)
7.8 x 3.8 x 3.1 Inches
Carton Dimensions (LxWxH):
21.7 x 15.7 x 13.8 Inches
Test Kit Weight (lbs):
0.90 LBS
Carton Weight (lbs):
18 LBS
Test Kit Components
Each Test Kit Includes:
10 COVID-19 Test Cartridges (LFIA)
10 Sterile Shallow Nasal Swabs
10 Sample Collection Tubes with buffer
10 Sample Collection Caps
Convenient Sample Collection Tube Stand
Instructions for Use (IFU)
Quick Reference Guide (QRG)
Testing Details
Collection/Analysis Location
CLIA Waived/POC
Sample Collection
Anterior Nasal Swab
Diagnostic Target:
Antigen
Time to Results:
15 Minutes
Shelf life:
12 Months
Intended Use
Qualitative detection of nucleocapsid protein antigen from SARSCoV-2 in direct anterior nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first five (5) days of symptom onset. Emergency use of this test is limited to authorized laboratories.
SPERA™ Product Documentation
In the USA, the SPERA™ COVID-19 Antigen Test has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high, or waived complexity tests. The SPERA™ COVID-19 Ag Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
